This year’s American Academy of Dermatology (AAD) Annual Meeting is already in full swing in Boston.
Nicolle Maquignon, VIPOC General secretary, reports from the GVF session: "Amit G Pandya, President, welcomed the participants. His speech was, as usual, very warming and showed how much he cares for the patients: find new resources, spread good information, give emotional as well as educational support to the individuals with vitiligo, educate the doctors, empower people to live well with vitiligo. <...> Doctors and scientists focused on the role of the patients and the groups support, in their studies, and are more and more aware about the burden, showing and talking about “humanity” in their relations with the patients."
All eyes will be on Incyte tomorrow as it reveals details on two Phase III trials studying its JAK1/JAK2 inhibitor ruxolitinib cream for vitiligo. To recap, the FDA extended its review of ruxolitinib in vitiligo for three months from 18 April to 18 July. Ruxolitinib is currently available for atopic dermatitis under the brand name Opzelura, and a potential expansion to vitiligo is key for Incyte's plans to diversify its revenue base. A similar delay happened when the company sought FDA approval for the cream in atopic dermatitis, but it eventually received FDA approval in the mild-to-moderate setting in patients 12 years old and over.
Photo (c) Nicolle Maquignon: Prof. John Harris, MD, Department of Dermatology at the University of Massachusetts Medical School presents “The vitiligo pathogenesis and updated emerging treatments”
- I have a new job - should I tell colleagues about my vitiligo?
If you are starting a new job and you are concerned about stares and questions about your skin, try a proactive approach. When the time is right and you are feeling comfortable,...
- Can chemicals cause vitiligo?
It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...
- What is vitiligo?
Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Cont...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.